Search
Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine
go.drugbank.com/drugs/DB10061ApprovedInvestigational[A253277] Several serogroups of _N. meningitidis_ - A, B, C, Y, and W-135 - known to cause meningococcal infections have been identified. … diphtheriae_ CRM197 protein carrier, resulting in four drug substances contained in each dose of vaccine.
Synonyms: Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccineHuman Rho(D) immune globulin
go.drugbank.com/drugs/DB11597ApprovedIt was approved by FDA as treatment for suppression of rhesus (Rh) isoimmunization or chronic immune thrombocytopenic purpura (ITP) in adults. … Human Rho(D) immune globulin is a medicine given by intramuscular or intravenous injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn).
Products: rhophylac 300 microgram/2ml,solution for injection in pre-filled syringeMaribavir
go.drugbank.com/drugs/DB06234ApprovedInvestigational[A242557] Maribavir is novel in that it instead targets the CMV pUL97 kinase, thereby providing an effective alternative treatment option in cases of resistant infections. … Maribavir is an inhibitor of the cytomegalovirus (CMV; HHV5) pUL97 kinase which is used to treat CMV infections in patients post-transplantation.
Capromab pendetide
go.drugbank.com/drugs/DB00089ApprovedWithdrawnWhen linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer. … Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate
Categories: Compounds used in a research, industrial, or household settingSynonyms: Indium In 111 capromab pendetideAurothioglucose
go.drugbank.com/drugs/DB09121ApprovedWithdrawnContemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis [A32326].
Cilastatin
go.drugbank.com/drugs/DB01597ApprovedInvestigational[L7628] A newer triple-drug product was approved in July 2019 under the trade name Recarbrio which also contains [relebactam].[L4894] … Cilastatin is an inhibitor of renal dehydropeptidase, an enzyme responsible for both the metabolism of thienamycin beta-lactam antibiotics as well as conversion of leukotriene D4 to leukotriene E4.
Mixtures: IMIPENEM/CILASTATINA POLVO PARA RECONSTITUIR A SOLUCIÓN INYECTABLE, IMIPENEM E CILASTATINA SUNSynonyms: (Z)-(S)-6-carboxy-6-[(S)-2,2-dimethylcyclopropanecarboxamido]hex-5-enyl-L-cysteine, (L)-7-(2-Amino-2-carboxy-ethylsulfanyl)-2-[(2,2-dimethyl-cyclopropanecarbonyl)-amino]-hept-2-enoic acidSynthetic Conjugated Estrogens, B
go.drugbank.com/drugs/DB09318ApprovedHowever, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control … Estrogens act by binding to estrogen receptors on a wide variety of tissues in the body and modulating the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone
mRNA-1010
go.drugbank.com/drugs/DB22484Approvedbenefit to be confirmed in a postmarketing trial. … [L64058] Each dose contains three mRNAs encapsulated in lipid nanoparticles, each encoding the hemagglutinin (HA) glycoprotein of one influenza strain recommended for the season; after intramuscular injection
Rozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigational[A260192] As a result, the main clinical manifestation of myasthenia gravis is easily fatigable or persistent muscle weakness. … Rozanolixizumab is a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P) targeting the immunoglobulin G (IgG).
Eculizumab
go.drugbank.com/drugs/DB01257ApprovedInvestigational[L6919] In Q1 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of two formulations of eculizumab indicated for the treatment of paroxysmal nocturnal hemoglobinuria … [L6919,A2245,A2246] Eculizumab was granted FDA approval on 16 March 2007.